dose conversion semaglutide to tirzepatide Switching from Tirzepatide Dosage Guide for Weight
Description
Wegovy (semaglutide) a once-weekly GLP-1 injection approved for chronic weight management alongside diet and exercise
GLP-1 receptor agonists are administered via subcutaneous injection into the fatty tissue beneath the skin, typically in the abdomen, thigh, or upper arm
Over 84 weeks, the average weight loss was 25.5% with tirzepatide compared with 23.0% with CagriSema
Pricing transparency at the maintenance dose
